Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | LCK | P06239 | 3/20 | 0.64 |
| ▸ | KIT | P10721 | 3/20 | 0.64 |
| ▸ | KDR | P35968 | 3/20 | 0.64 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.64 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.57 |
| ▸ | RAF1 | P04049 | 1/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1313546 | 0.94 | MAPK14 (0.89) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL1311180 | 0.92 | MAPK14 (0.85) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL1311908 | 0.91 | MAPK14 (0.84) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL1311246 | 0.91 | MAPK14 (1.00) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL1313052 | 0.91 | MAPK14 (0.83) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL1310738 | 0.90 | MAPK14 (0.82) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL1313213 | 0.90 | MAPK14 (1.00) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL1311421 | 0.90 | MAPK14 (0.81) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL1313295 | 0.90 | MAPK14 (0.81) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL1311225 | 0.89 | MAPK14 (1.00) | MAPK14LCKKITKDRMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455495-B2 | Pyridazino-pyridinone compounds and methods of use | AMGEN INC. (US) | 2013-06-04 | — | — | US | claimed |
| EP-2334674-B1 | Pyridazino- pyridinone compounds for the treatment of protein kinase mediated diseases. | AMGEN INC (US) | 2012-06-06 | — | — | EP | claimed |
| US-20110275629-A1 | Pyridazino-pyridinone Compounds and Methods of Use | AMGEN INC. (US) | 2011-11-10 | — | — | US | claimed |
| EP-2334674-A1 | PYRIDAZINO- PYRIDINONE COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE MEDIATED DISEASES. | Amgen, Inc (US) | 2011-06-22 | — | — | EP | claimed |
| WO-2010025201-A1 | PYRIDAZINO- PYRIDINONE COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE MEDIATED DISEASES. | AMGEN INC. (US) | 2010-03-04 | — | — | WO | claimed |
| US-8455495-B2 | Pyridazino-pyridinone compounds and methods of use | AMGEN INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455495-B2 | Pyridazino-pyridinone compounds and methods of use | AMGEN INC. (US) | 2013-06-04 | — | — | US | disclosed |
| EP-2334674-B1 | Pyridazino- pyridinone compounds for the treatment of protein kinase mediated diseases. | AMGEN INC (US) | 2012-06-06 | — | — | EP | disclosed |
| EP-2334674-B1 | Pyridazino- pyridinone compounds for the treatment of protein kinase mediated diseases. | AMGEN INC (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20110275629-A1 | Pyridazino-pyridinone Compounds and Methods of Use | AMGEN INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275629-A1 | Pyridazino-pyridinone Compounds and Methods of Use | AMGEN INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2334674-A1 | PYRIDAZINO- PYRIDINONE COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE MEDIATED DISEASES. | Amgen, Inc (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010025201-A1 | PYRIDAZINO- PYRIDINONE COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE MEDIATED DISEASES. | AMGEN INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| WO-2010025201-A1 | PYRIDAZINO- PYRIDINONE COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE MEDIATED DISEASES. | AMGEN INC. (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275629-A1 | Pyridazino-pyridinone Compounds and Methods of Use | MAPK1, MAP3K1, MAP4K2 | MAPK14 46/4885LCK 255/4885KIT 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.